Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001

E. J. Threlfall; Ian Fisher; C. Berghold; P. Gerner-Smidt; H. Tschäpe; M. Cormican; I. Luzzi; F. Schnieder; W. Wannet; J. Machado; G. Edwards

doi:10.1016/S0924-8579(03)00262-0

Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001

E. J. Threlfall^*, Ian Fisher, C. Berghold, P. Gerner-Smidt, H. Tschäpe, M. Cormican, I. Luzzi, F. Schnieder, W. Wannet, J. Machado, G. Edwards

^*Corresponding author for this work

Public Health England

Research output: Contribution to journal › Article › peer-review

45 Citations (Scopus)

Abstract

Results of antimicrobial sensitivity tests for strains of Salmonella enterica serotypes Typhi and Paratyphi A isolated from patients in ten European countries between 1999 and 2001 have been transferred electronically to the Enter-net surveillance hub. For Typhi between 22 and 29% of isolates were multiresistant (to four drugs or more) with decreased susceptibility to ciprofloxacin (MIC 0.25-1.0 mg/l) increasing from 20% in 1999 to 26% in 2001. Nineteen of 169 (11%) strains with decreased ciprofloxacin susceptibility were sensitive to nalidixic acid. For Paratyphi A multiple resistance increased from 9% in 1999 to 25% in 2001 and decreased ciprofloxacin susceptibility from 6 to 17%. Clinicians should be aware of the possibility of treatment failures when fluoroquinolones are used as the first-line drug for infections with Typhi and Paratyphi A, particularly for patients recently returning from areas where drug-resistant strains are endemic.

Original language	English
Pages (from-to)	487-491
Number of pages	5
Journal	International Journal of Antimicrobial Agents
Volume	22
Issue number	5
DOIs	https://doi.org/10.1016/S0924-8579(03)00262-0
Publication status	Published - Nov 2003

Bibliographical note

Funding Information:
The authors would like to acknowledge the support and contribution to the surveillance network of all the Enter-net participants. Enter-net is funded by the European Commission, Directorate General Health and Consumer Protection, Directorate G, Public Health, Unit 4—Communicable, Rare and Emerging Diseases, contract no 2000CVG4-037.

Keywords

Ciprofloxacin
Drug resistance
Europe
S. Paratyphi A
Salmonella Typhi

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0924-8579(03)00262-0

Cite this

Threlfall, E. J., Fisher, I., Berghold, C., Gerner-Smidt, P., Tschäpe, H., Cormican, M., Luzzi, I., Schnieder, F., Wannet, W., Machado, J., & Edwards, G. (2003). Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001. International Journal of Antimicrobial Agents, 22(5), 487-491. https://doi.org/10.1016/S0924-8579(03)00262-0

@article{bb971363709e4fb98cfe361cd0c246a1,

title = "Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001",

abstract = "Results of antimicrobial sensitivity tests for strains of Salmonella enterica serotypes Typhi and Paratyphi A isolated from patients in ten European countries between 1999 and 2001 have been transferred electronically to the Enter-net surveillance hub. For Typhi between 22 and 29% of isolates were multiresistant (to four drugs or more) with decreased susceptibility to ciprofloxacin (MIC 0.25-1.0 mg/l) increasing from 20% in 1999 to 26% in 2001. Nineteen of 169 (11%) strains with decreased ciprofloxacin susceptibility were sensitive to nalidixic acid. For Paratyphi A multiple resistance increased from 9% in 1999 to 25% in 2001 and decreased ciprofloxacin susceptibility from 6 to 17%. Clinicians should be aware of the possibility of treatment failures when fluoroquinolones are used as the first-line drug for infections with Typhi and Paratyphi A, particularly for patients recently returning from areas where drug-resistant strains are endemic.",

keywords = "Ciprofloxacin, Drug resistance, Europe, S. Paratyphi A, Salmonella Typhi",

author = "Threlfall, {E. J.} and Ian Fisher and C. Berghold and P. Gerner-Smidt and H. Tsch{\"a}pe and M. Cormican and I. Luzzi and F. Schnieder and W. Wannet and J. Machado and G. Edwards",

note = "Funding Information: The authors would like to acknowledge the support and contribution to the surveillance network of all the Enter-net participants. Enter-net is funded by the European Commission, Directorate General Health and Consumer Protection, Directorate G, Public Health, Unit 4—Communicable, Rare and Emerging Diseases, contract no 2000CVG4-037.",

year = "2003",

month = nov,

doi = "10.1016/S0924-8579(03)00262-0",

language = "English",

volume = "22",

pages = "487--491",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "5",

}

Threlfall, EJ, Fisher, I, Berghold, C, Gerner-Smidt, P, Tschäpe, H, Cormican, M, Luzzi, I, Schnieder, F, Wannet, W, Machado, J & Edwards, G 2003, 'Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001', International Journal of Antimicrobial Agents, vol. 22, no. 5, pp. 487-491. https://doi.org/10.1016/S0924-8579(03)00262-0

TY - JOUR

T1 - Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001

AU - Threlfall, E. J.

AU - Fisher, Ian

AU - Berghold, C.

AU - Gerner-Smidt, P.

AU - Tschäpe, H.

AU - Cormican, M.

AU - Luzzi, I.

AU - Schnieder, F.

AU - Wannet, W.

AU - Machado, J.

AU - Edwards, G.

N1 - Funding Information: The authors would like to acknowledge the support and contribution to the surveillance network of all the Enter-net participants. Enter-net is funded by the European Commission, Directorate General Health and Consumer Protection, Directorate G, Public Health, Unit 4—Communicable, Rare and Emerging Diseases, contract no 2000CVG4-037.

PY - 2003/11

Y1 - 2003/11

N2 - Results of antimicrobial sensitivity tests for strains of Salmonella enterica serotypes Typhi and Paratyphi A isolated from patients in ten European countries between 1999 and 2001 have been transferred electronically to the Enter-net surveillance hub. For Typhi between 22 and 29% of isolates were multiresistant (to four drugs or more) with decreased susceptibility to ciprofloxacin (MIC 0.25-1.0 mg/l) increasing from 20% in 1999 to 26% in 2001. Nineteen of 169 (11%) strains with decreased ciprofloxacin susceptibility were sensitive to nalidixic acid. For Paratyphi A multiple resistance increased from 9% in 1999 to 25% in 2001 and decreased ciprofloxacin susceptibility from 6 to 17%. Clinicians should be aware of the possibility of treatment failures when fluoroquinolones are used as the first-line drug for infections with Typhi and Paratyphi A, particularly for patients recently returning from areas where drug-resistant strains are endemic.

AB - Results of antimicrobial sensitivity tests for strains of Salmonella enterica serotypes Typhi and Paratyphi A isolated from patients in ten European countries between 1999 and 2001 have been transferred electronically to the Enter-net surveillance hub. For Typhi between 22 and 29% of isolates were multiresistant (to four drugs or more) with decreased susceptibility to ciprofloxacin (MIC 0.25-1.0 mg/l) increasing from 20% in 1999 to 26% in 2001. Nineteen of 169 (11%) strains with decreased ciprofloxacin susceptibility were sensitive to nalidixic acid. For Paratyphi A multiple resistance increased from 9% in 1999 to 25% in 2001 and decreased ciprofloxacin susceptibility from 6 to 17%. Clinicians should be aware of the possibility of treatment failures when fluoroquinolones are used as the first-line drug for infections with Typhi and Paratyphi A, particularly for patients recently returning from areas where drug-resistant strains are endemic.

KW - Ciprofloxacin

KW - Drug resistance

KW - Europe

KW - S. Paratyphi A

KW - Salmonella Typhi

UR - http://www.scopus.com/inward/record.url?scp=10744226561&partnerID=8YFLogxK

U2 - 10.1016/S0924-8579(03)00262-0

DO - 10.1016/S0924-8579(03)00262-0

M3 - Article

C2 - 14602366

AN - SCOPUS:10744226561

SN - 0924-8579

VL - 22

SP - 487

EP - 491

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 5

ER -

Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this